03598nam a22006015i 45000010014000000030009000140050017000230060019000400070015000590080041000740200018001150240031001330350021001640400033001850410008002180440015002260720023002411000083002642450062003472640051004092640011004603000031004713360026005023370026005283380036005543470024005905050545006145060104011595200921012635380049021845460016022335880112022496500038023617730117023998560042025168560049025588560080026079120088026879120016027759120016027919120017028079120015028249120017028399120016028569120016028729120014028889120015029029120024029179120014029419120014029559120015029699120012029849781626374102DE-B159720220629043637.0m|||||o||d||||||||cr || ||||||||220629t20222004cou    fo  d z      eng d  a97816263741027 a10.1515/97816263741022doi  a(DE-B1597)623427  aDE-B1597bengcDE-B1597erda0 aeng  acoucUS-CO 7aMED0360002bisacsh1 aCeccoli, Stephen J., eauthor.4aut4http://id.loc.gov/vocabulary/relators/aut10aPill Politics :bDrugs and the FDA /cStephen J. Ceccoli. 1aBoulder : bLynne Rienner Publishers, c[2022] 4c©2004  a1 online resource (211 p.)  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  atext filebPDF2rda00tFrontmatter -- tContents -- tTables and Figures -- tAcknowledgments -- t1. Putting the FDA into Perspective -- t2. The Politics of Assessing Drugs -- t3. An Evolving Regulatory Balance -- t4. The Drug Lag Debate and Demands for Reform -- t5. A Grand Compromise and the Shift to a New Era -- t6. Whither the FDA? -- t7. Protecting and Promoting Public Health in the United States -- tAppendix: Drug Development and the FDA’s Approval Process -- tList of Abbreviations -- tNotes -- tBibliography -- tIndex -- tAbout the Book0 arestricted accessuhttp://purl.org/coar/access_right/c_16ecfonline access with authorization2star  aFrom aspirin to Viagra to the latest cancer treatment, the Food and Drug Administration acts as a gatekeeper determining what medicines are legally available in the United States. But in fulfilling that regulatory role, Stephen Ceccoli argues, the FDA may inadvertently be promoting new drugs at the expense of public health.The FDA's initial mandate to protect health grew out of pharmaceutical-related disasters in the early 1900s. Later criticisms that the agency's approach impeded industry competitiveness and failed to meet public need, however, led to a political compromise on its mission. The new FDA has cut its review time nearly in half and allows direct-to-consumer advertising, off-label promotion of drugs, and the "fast-tracking" of treatments. Ceccoli convincingly shows that this approval process, while redressing valid complaints, is also creating a new complex of problems that must be resolved.  aMode of access: Internet via World Wide Web.  aIn English.0 aDescription based on online resource; title from PDF title page (publisher's Web site, viewed 29. Jun 2022) 7aMEDICAL / Health Policy.2bisacsh08iTitle is part of eBook package:dDe GruytertLynne Rienner Press Complete eBook-Package 2013-2000z978311078425140uhttps://doi.org/10.1515/978162637410240uhttps://www.degruyter.com/isbn/9781626374102423Coveruhttps://www.degruyter.com/document/cover/isbn/9781626374102/original  a978-3-11-078425-1  Lynne Rienner Press Complete eBook-Package 2013-2000c2000d2013  aEBA_BACKALL  aEBA_CL_MDPM  aEBA_EBACKALL  aEBA_EBKALL  aEBA_ECL_MDPM  aEBA_EEBKALL  aEBA_ESTMALL  aEBA_PPALL  aEBA_STMALL  aGBV-deGruyter-alles  aPDA12STME  aPDA13ENGE  aPDA18STMEE  aPDA5EBK